IL22 and Hepatic steatosis: Another study reported that elevated levels of IL-22-producing ILC3s in the liver of HFD-induced MASH model were associated with reduced hepatic steatosis, while genetic deficiency of ILC3s worsened liver inflammation and fibrosis progression (Figure 2) (239).